United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares of Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the stock in a transaction dated Wednesday, July 8th. The stock was sold at an average price of $553.17, for a total transaction of $5,255,115.00. Following the completion of the transaction, the chief executive officer directly owned 40,513 shares of the company’s stock, valued at approximately $22,410,576.21. The trade was a 19.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

United Therapeutics Stock Performance

UTHR stock opened at $552.48 on Friday. United Therapeutics Corporation has a fifty-two week low of $272.12 and a fifty-two week high of $609.35. The company has a market capitalization of $23.45 billion, a price-to-earnings ratio of 20.39, a price-to-earnings-growth ratio of 1.82 and a beta of 0.58. The business’s 50 day moving average price is $557.18 and its two-hundred day moving average price is $529.32.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The firm had revenue of $781.50 million during the quarter, compared to analysts’ expectations of $797.40 million. During the same quarter in the previous year, the business earned $6.63 EPS. The company’s revenue for the quarter was down 1.6% compared to the same quarter last year. Sell-side analysts forecast that United Therapeutics Corporation will post 26.63 earnings per share for the current year.

Institutional Investors Weigh In On United Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Arjuna Capital lifted its position in United Therapeutics by 2.8% during the first quarter. Arjuna Capital now owns 662 shares of the biotechnology company’s stock valued at $393,000 after purchasing an additional 18 shares in the last quarter. Sage Rhino Capital LLC increased its position in United Therapeutics by 5.1% in the first quarter. Sage Rhino Capital LLC now owns 474 shares of the biotechnology company’s stock worth $281,000 after buying an additional 23 shares in the last quarter. Bryn Mawr Trust Advisors LLC raised its stake in shares of United Therapeutics by 5.4% in the first quarter. Bryn Mawr Trust Advisors LLC now owns 465 shares of the biotechnology company’s stock worth $276,000 after buying an additional 24 shares during the period. Meeder Advisory Services Inc. raised its stake in shares of United Therapeutics by 4.1% in the first quarter. Meeder Advisory Services Inc. now owns 661 shares of the biotechnology company’s stock worth $392,000 after buying an additional 26 shares during the period. Finally, Independent Advisor Alliance lifted its position in shares of United Therapeutics by 3.3% during the 4th quarter. Independent Advisor Alliance now owns 833 shares of the biotechnology company’s stock valued at $406,000 after buying an additional 27 shares in the last quarter. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

UTHR has been the topic of a number of research reports. Cantor Fitzgerald boosted their target price on shares of United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a report on Thursday, March 12th. Morgan Stanley set a $516.00 price target on shares of United Therapeutics in a research note on Thursday, May 7th. Raymond James Financial initiated coverage on shares of United Therapeutics in a research report on Friday, April 10th. They set an “outperform” rating and a $700.00 price target for the company. Weiss Ratings reissued a “buy (b)” rating on shares of United Therapeutics in a research note on Thursday, June 11th. Finally, HC Wainwright upped their price objective on shares of United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a report on Tuesday, March 31st. Ten analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $646.00.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.